{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.155","value":"0.054"},{"groupId":"OG001","spread":"0.151","value":"0.117"},{"groupId":"OG002","spread":"0.165","value":"0.109"}]}],"title":"Index Score (US Algorithm) Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.149","value":"0.051"},{"groupId":"OG001","spread":"0.172","value":"0.113"},{"groupId":"OG002","spread":"0.173","value":"0.129"}]}],"title":"Index Score (US Algorithm) Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.230","value":"0.074"},{"groupId":"OG001","spread":"0.221","value":"0.167"},{"groupId":"OG002","spread":"0.237","value":"0.159"}]}],"title":"Index Score (UK Algorithm) Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.218","value":"0.075"},{"groupId":"OG001","spread":"0.254","value":"0.162"},{"groupId":"OG002","spread":"0.250","value":"0.185"}]}],"title":"Index Score (UK Algorithm) Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"227"},{"groupId":"OG002","value":"216"}],"units":"Participants"}],"description":"European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug , with a baseline value and at least 1 post-baseline value. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.","reportingStatus":"POSTED","timeFrame":"Baseline Week 12; Baseline Week 24","title":"Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}